The panel discusses long-term data showing more limited benefit of IO-IO therapy versus TKI regimens for favorable risk RCC patients and implications for their risk-adapted treatment approach.
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.
Radioligand Therapy Combo Boosts rPFS in PSMA+ Metastatic HSPC
Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.
Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC
Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.
Disitamab Vedotin/Toripalimab Combo Prolongs Survival in Frontline HER2+ Urothelial Cancer
Disitamab vedotin plus toripalimab achieved a median 13.1-month PFS and median 31.5-month OS in patients with HER2-expressing advanced urothelial carcinoma.
Enzalutamide/Leuprolide Regimen Reduces Risk of Death in Prostate Cancer
At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.